Episode Details

Back to Episodes
Could Glaucoma Surgery Become a 10-Minute Office Procedure? First Human Results From OBi Core

Could Glaucoma Surgery Become a 10-Minute Office Procedure? First Human Results From OBi Core

Published 2 months ago
Description

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/could-glaucoma-surgery-become-a-10-minute-office-procedure-first-human-results-from-obi-core

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

Could Glaucoma Surgery Become a 10-Minute Office Procedure? First Human Results From OBi Core Short answer: OBi Core is one of the more interesting new glaucoma procedures because it attempts to combine the pressure-lowering power of filtration surgery with the convenience of an office-based slit-lamp procedure. But the current evidence is still extremely early. The publicly reported human experience consists of a small first-in-human series of approximately 10 eyes with detailed results, followed by a company update describing 11 treated eyes. Follow-up is short, patient-level data are not publicly available, and approximately 30% of eyes required reintervention in the initial detailed report. () The technology is therefore promising, but not yet proven to replace trabeculectomy. Its most important scientific question is not whether it can lower pressure initially. The early data suggest that it can. The difficult question is whether the subconjunctival bleb can remain functional for years without recreating the fibrosis, needling, medication, and monitoring burden of conventional filtering surgery. The Bottom Line OBi Core is not a conventional angle-based minimally invasive glaucoma surgery. It creates a direct pathway from the anterior chamber to a subconjunctival or sub-Tenon filtration space. The device appears to use a 27-gauge, 6-millimeter punch needle to create an oblique scleral microchannel approximately 150 ± 50 micrometers in diameter. () It does create a subconjunctival filtration bleb, meaning it shares the central biological weakness of trabeculectomy, XEN Gel Stent, and PreserFlo MicroShunt: wound healing and fibrosis can eventually reduce flow. The detailed first-in-human report involved 10 eyes followed for up to approximately 6 weeks. Mean intraocular pressure fell from 30.1 to 10.2 millimeters of mercury, a calculated absolute reduction of 19.9 millimeters of mercury, or approximately 66%. Mean glaucoma medications fell from 2.2 to 0.8, an absolute reduction of 1.4 medications, or approximately 64%. Seventy percent of eyes reportedly achieved complete success under the study definition, and approximately 78% were medication-free, although the denominators and patient-level data were not fully disclosed. Thirty percent required reintervention, including repeat OBi Core procedures or other filtration procedures. The reasons for those interventions have not been publicly separated into fibrosis, obstruction, inadequate flow, or surgical learning-curve effects. () A September 2026 company update described 11 treated eyes, including mild, moderate, and advanced glaucoma, with early pressures in the single digits to low teens and no reported device- or procedure-related adverse events. No detailed aggregate results from the eleventh eye were provided. () The “10-minute” description is not yet supported by a published procedural-time dataset. The channel-creation step may take seconds, but the full visit—including preparation, anesthesia, mitomycin C, intraocular pressure management, and postoperative testing—has not been formally reported. What Is OBi Core? Manufacturer and development status OBi Core is being developed by Hexiris Ophthalmics, a Canadian company based in Dieppe, New Brunswick. Hexiris describes OBi Core as a device for minimally invasive

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us